MAI Capital Management Has $19.69 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• MAI Capital Management increased its holdings in Thermo Fisher Scientific Inc. by 75.9% in Q1, bringing its stake to 39,577 shares valued at approximately $19.69 million.
• The company reported earnings of $5.36 per share, exceeding analyst estimates, and had a net revenue of $10.86 billion for the quarter, reflecting a 2.9% year-over-year increase.
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43, which will be payable on October 15th, reflecting an annualized dividend yield of 0.3%.

MAI Capital Management increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 75.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,577 shares of the medical research company's stock after buying an additional 17,071 shares during the period. MAI Capital Management's holdings in Thermo Fisher Scientific were worth $19,694,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $37,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $493.05 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a 50-day moving average price of $452.50 and a 200 day moving average price of $454.32. The stock has a market cap of $186.18 billion, a PE ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,896 shares of company stock worth $13,603,438. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.